𝔖 Bobbio Scriptorium
✦   LIBER   ✦

148 90Y-anti-CD20 monoclonal antibody therapy for recurrent B cell lymphoma

✍ Scribed by Susan J. Knox; Michael L. Goris; Kirk D. Trisler; Tom A. Davis; Tina-Marie Liles; Sherry F. Fowler; Paul C. Chinn; Ron A. Morena; Brian K. Dallaire; Antonio J. Grillo-López; Nimisha Deb; Mark Becker; Carol M. Marquez; Shou-cheng Ning; Ron Levy

Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
118 KB
Volume
32
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of B-cell non-Hodgkin's lympho
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
✍ Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have

Synergistic cytotoxicity of iodine-131-a
Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas
✍ Timothy A. Johnson; Oliver W. Press 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 231 KB

Preliminary clinical trials suggest that iodine-131 ( 131 I)labeled anti-CD20 monoclonal antibodies (MAbs) are effective single agents for the treatment of relapsed non-Hodgkin's B-cell lymphomas. However, despite high initial response rates, most patients treated in this manner will eventually rela

The advantage of residualizing radiolabe
The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody
✍ M. Jules Mattes; Lisa B. Shih; Serengulam V. Govindan; Robert M. Sharkey; Gaik L 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 104 KB

CD22 antibodies (Abs) bound to B-cell lymphomas are known to be internalized and catabolized rapidly. Therefore, it would be expected that use of CD22 as a target for radioimmunotherapy should be enhanced by the use of "residualizing" radiolabels, which are trapped within the cell after catabolism o